Cardiovascular Screening Practices and Statin Prescription Habits in Patients with Psoriasis among Dermatologists, Rheumatologists and Primary Care Physicians.


Journal

Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310

Informations de publication

Date de publication:
28 Mar 2023
Historique:
received: 25 10 2022
accepted: 30 01 2023
medline: 30 3 2023
entrez: 29 3 2023
pubmed: 30 3 2023
Statut: epublish

Résumé

Patients with psoriasis have a higher prevalence of cardiovascular risk factors. This study evaluated cardiovascular screening practices and statin prescribing habits among dermatologists, rheumatologists and primary care physicians (PCPs) through an online questionnaire, which was distributed through the Spanish scientific societies of the above-mentioned specialties. A total of 299 physicians (103 dermatologists, 94 rheumatologists and 102 PCPs) responded to the questionnaire. Of these, 74.6% reported screening for smoking, 37.8% for hypertension, 80.3% for dyslipidaemia, and 79.6% for diabetes mellitus. Notably, only 28.4% performed global screening, defined as screening for smoking, hypertension, dyslipidaemia, and diabetes mellitus by the same physician, and 24.4% reported calculating 10-year cardiovascular disease (CVD) risk, probably reflecting a lack of comprehensive cardiovascular risk assessment in these patients. This study also identified unmet needs for awareness of cardiovascular comorbidities in psoriasis and corresponding screening and treatment recommendations among PCPs. Of PCPs, 61.2% reported not being aware of the association between psoriasis and CVD and/or not being aware of its screening recommendations, and 67.6% did not consider psoriasis as a risk-enhancing factor when deciding on statin prescription. Thirteen dermatologists (12.6%) and 35 rheumatologists (37.2%) reported prescribing statins. Among those who do not prescribe, 49.7% would be willing to start their prescription.

Identifiants

pubmed: 36987537
doi: 10.2340/actadv.v103.5087
pmc: PMC10077140
doi:

Substances chimiques

Hydroxymethylglutaryl-CoA Reductase Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

adv5087

Références

J Am Acad Dermatol. 2013 Apr;68(4):654-662
pubmed: 23360868
Sci Rep. 2017 Oct 23;7(1):13831
pubmed: 29062018
Circulation. 2017 Jul 18;136(3):263-276
pubmed: 28483812
J Am Acad Dermatol. 2019 May;80(5):1332-1343
pubmed: 30590074
Br J Dermatol. 2016 Aug;175(2):348-56
pubmed: 26990294
Am J Med. 2011 Aug;124(8):775.e1-6
pubmed: 21787906
Br J Dermatol. 2014 Feb;170(2):304-14
pubmed: 24117435
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
J Drugs Dermatol. 2013 Jan;12(1):e14-9
pubmed: 23377342
J Invest Dermatol. 2013 Oct;133(10):2340-2346
pubmed: 23528816
J Am Acad Dermatol. 2015 Nov;73(5):872-4.e4
pubmed: 26475543
Eur Heart J. 2021 Sep 7;42(34):3227-3337
pubmed: 34458905
Circulation. 2019 Jun 18;139(25):e1082-e1143
pubmed: 30586774
J Am Acad Dermatol. 2019 Apr;80(4):1073-1113
pubmed: 30772097
PLoS One. 2019 Feb 8;14(2):e0211808
pubmed: 30735527
Actas Dermosifiliogr (Engl Ed). 2021 May;112(5):425-433
pubmed: 33290733
Endocr Pract. 2017 Apr;23(Suppl 2):1-87
pubmed: 28437620
Acta Derm Venereol. 2016 Nov 2;96(7):972-973
pubmed: 27070293
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Ann Intern Med. 2015 Nov 17;163(10):778-86
pubmed: 26458123
Medicine (Baltimore). 2018 Jul;97(27):e11394
pubmed: 29979432
JAAD Int. 2020 Dec 01;2:31-36
pubmed: 34409351
JAMA. 2006 Oct 11;296(14):1735-41
pubmed: 17032986
JAMA Dermatol. 2022 Mar 01;158(3):252-259
pubmed: 35044419
JAMA Dermatol. 2015 Feb;151(2):161-9
pubmed: 25322196
J Am Heart Assoc. 2020 Sep 15;9(18):e016956
pubmed: 32914667
J Am Acad Dermatol. 2012 Sep;67(3):357-62
pubmed: 22079041
J Am Acad Dermatol. 2006 Nov;55(5):829-35
pubmed: 17052489
J Invest Dermatol. 2012 Mar;132(3 Pt 1):556-62
pubmed: 22113483
Arch Dermatol Res. 2021 Apr;313(3):163-171
pubmed: 32393987
J Rheumatol. 2018 Mar;45(3):378-384
pubmed: 29419462
J Am Acad Dermatol. 2018 Feb;78(2):315-322.e1
pubmed: 29128465
Eur J Prev Cardiol. 2022 Mar 30;29(4):591-598
pubmed: 33624060
Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):787-798
pubmed: 30760013
Circulation. 2019 Sep 10;140(11):e596-e646
pubmed: 30879355
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28
pubmed: 30559228
J Invest Dermatol. 2009 Oct;129(10):2411-8
pubmed: 19458634
Atherosclerosis. 2019 Nov;290:140-205
pubmed: 31591002
Ann Transl Med. 2016 Mar;4(6):111
pubmed: 27127764
J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2058-2073
pubmed: 29992631
Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2658-68
pubmed: 25341795

Auteurs

Emilio Berna-Rico (E)

Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.

Carlota Abbad-Jaime de Aragon (C)

Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.

Angel Garcia-Aparicio (A)

Department of Rheumatology, Hospital Universitario de Toledo, Toledo, Spain.

David Palacios-Martinez (D)

Centro de Salud Universitario Isabel II, Parla, Madrid, Spain.

Asuncion Ballester-Martinez (A)

Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.

Jose-M Carrascosa (JM)

Department of Dermatology, Hospital Universitari Germans Trias i Pujol. Universitat Autònoma de Barcelona. IGTP. Badalona, Spain.

Pablo De la Cueva (P)

Department of Dermatology, Infanta Leonor Hospital, Madrid, Spain.

Cristina Anton (C)

Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain.

Carlos Azcarraga-Llobet (C)

Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.

Emilio Garcia-Mouronte (E)

Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.

Belen De Nicolas-Ruanes (B)

Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.

Lluis Puig (L)

Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain.

Pedro Jaen (P)

Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.

Nehal N Mehta (NN)

Laboratory of Inflammation & Cardiometabolic diseases, Cardiovascular Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.

Joel M Gelfand (JM)

Department of Dermatology and Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Alvaro Gonzalez-Cantero (A)

Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain; Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain. alvarogc261893@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH